**Name of Journal:** *World Journal of Psychiatry*

**Manuscript NO:** 90461

**Manuscript Type:** MINIREVIEWS

**Navigating the intersection of psychiatry and ophthalmology: A comprehensive review of depression and anxiety management in glaucoma patients**

Ramesh PV *et al*. Mind and sight: A psychiatric-ophthalmologic perspective

Prasanna Venkatesh Ramesh, Arvind Kumar Morya, Ashik Azad, Pavithra Pannerselvam, Aji Kunnath Devadas, Sai Thaejesvi Gopalakrishnan, Shruthy Vaishali Ramesh, Ajanya K Aradhya

**Prasanna Venkatesh Ramesh,** Department of Glaucoma and Research, Mahathma Eye Hospital Private Limited, Trichy 620017, Tamil Nadu, India

**Arvind Kumar Morya,** Department of Ophthalmology, All India Institute of Medical Sciences, Hyderabad 508126, Telangana, India

**Ashik Azad, Aji Kunnath Devadas, Ajanya K Aradhya,** Department of Optometry and Visual Science, Mahathma Eye Hospital Private Limited, Trichy 620017, Tamil Nadu, India

**Pavithra Pannerselvam, Sai Thaejesvi Gopalakrishnan,** Mahathma Eye Hospital Private Limited, Trichy 620017, Tamil Nadu, India

**Shruthy Vaishali Ramesh,** Department of Cataract and Refractive Surgery, Mahathma Eye Hospital Private Limited, Trichy 620017, Tamil Nadu, India

**Author contributions:** Ramesh PV and Morya AK played big roles they helped plan and carry out the study, and carefully looked at the results; Azad A took the lead in designing the study and writing the manuscript; Pannerselvam P had a key role in coming up with the study’s main ideas and adding helpful suggestions; Ramesh SV made sure the data we used was reliable; Devadas AK, Gopalakrishnan ST, and Aradhya AK provided valuable expertise in reviewing and editing the manuscript; and all authors have carefully reviewed and given their approval for the final manuscript.

**Corresponding author: Prasanna Venkatesh Ramesh, DNB, MBBS, MS, Doctor,** Department of Glaucoma and Research, Mahathma Eye Hospital Private Limited, No. 6 Seshapuram, Tennur, Trichy 620017, Tamil Nadu, India. email2prajann@gmail.com

**Received:** December 4, 2023

**Revised:** January 28, 2024

**Accepted:** February 29, 2024

**Published online:**

**Abstract**

Glaucoma, a prevalent and debilitating eye disease, has long been associated with vision impairment and blindness. However, recent research has shed light on the often-underestimated psychological dimensions of this condition. Anxiety and depression, two pervasive psychiatric comorbidities, have been increasingly recognized among glaucoma patients. This comprehensive review aims to explore the intricate relationship between psychiatry and ophthalmology, in the context of managing depression and anxiety in glaucoma patients. By meticulously examining peer-reviewed literature, we synthesize current knowledge on the prevalence, risk factors, and underlying mechanisms of anxiety and depression in glaucoma. The evidence reveals that glaucoma patients face an elevated risk of experiencing these mood disorders. Factors such as progressive vision loss, complex medication regimens, and the fear of further visual deterioration contribute to their vulnerability. Moreover, we delve into the bidirectional relationship between glaucoma and mood disorders, shedding light on the complex interplay between ocular and emotional health. Our review investigates the implications of anxiety and depression on glaucoma management, including their potential impact on treatment adherence, disease progression, and overall quality of life. We also explore the neurobiological pathways linking glaucoma and mood disorders, providing a foundation for future research and potential therapeutic interventions. In conclusion, recognizing the psychological burden carried by glaucoma patients is essential for holistic and patient-centered care. This review underscores the pressing need for integrated approaches that bring together ophthalmological and psychiatric expertise to optimize the well-being of individuals facing the challenges of glaucoma. By addressing anxiety and depression in glaucoma care, healthcare providers can enhance the overall quality of life for these patients, ultimately leading to improved outcomes and a brighter future for those affected by this condition. This review offers valuable insight for healthcare practitioners and researchers, providing a concise overview of key topics and research in the field of managing depression and anxiety in glaucoma patients.

**Key Words:** Glaucoma; Psychiatry; Depression; Anxiety; Risk factors; Bidirectional relationship

Ramesh PV, Morya AK, Azad A, Pannerselvam P, Devadas AK, Gopalakrishnan ST, Ramesh SV, Aradhya AK. Navigating the intersection of psychiatry and ophthalmology: A comprehensive review of depression and anxiety management in glaucoma patients. *World J Psychiatry* 2024; In press

**Core Tip:** This literature review underscores the evolving perspective on glaucoma, traditionally viewed solely as an ocular ailment. It delves into the intricate interplay between glaucoma and mental health, shedding light on the psychological toll exacted by the relentless progression of vision loss. The bidirectional relationship between glaucoma, anxiety, and depression is explored, accentuating factors like progressive vision decline and medication intricacies. Emphasizing holistic patient care, the core recommendation advocates for collaborative efforts between ophthalmologists and psychiatrists to address depression and anxiety, recognizing their impact on treatment adherence, disease trajectory, and the overall well-being of individuals grappling with glaucoma.

**INTRODUCTION**

Glaucoma, traditionally perceived as a progressively debilitating ocular pathology, not only encroaches upon visual acuity (VA) but also casts a profound impact on the psychological fabric of affected individuals. The relentless progression of vision loss, coupled with the constant awareness of a potentially irreversible condition, places an immense psychological burden on patients. Recent research signifies a pivotal shift from the exclusive focus on its physical aspects to a more nuanced understanding of the psychological dimensions associated with the condition. This literature review explores the intersection of psychiatry and ophthalmology, dissecting the complexities of managing depression and anxiety in glaucoma patients. We analyze prevalence, risk factors, and mechanisms underlying mood disorders in glaucoma, unveiling the complex relationship between the conditions. Contributing factors, such as progressive vision loss and medication complexity, heighten susceptibility to mood disorders. The review explores the impact of anxiety and depression on treatment adherence, disease progression, and overall quality of life in glaucoma patients. Emphasizing holistic care, we advocate for integrated strategies involving both ophthalmologists and psychiatrists to enhance patient-centered care and quality of life.

**LITERATURE REVIEW**

A thorough search of the PubMed database was conducted, encompassing literature published from January 2000 to August 2023. The search utilized keywords such as “glaucoma”, “depression”, “anxiety”, “glaucoma and depression”, and “glaucoma and anxiety”. The selected studies included reviews, cross-sectional, case-control, prospective, and retrospective studies, with the primary focus on investigating the correlation between glaucoma and anxiety/depression and identifying potential risk factors. To maintain stringency, case reports and meta-analyses were excluded from consideration. Only studies written in English were included in the evaluation process. The retrieved articles underwent a careful manual review to eliminate duplicates, resulting in the selection 55 articles from the screened abstracts (Table 1).

**PREVALENCE AND RISK FACTORS OF ANXIETY AND DEPRESSION IN GLAUCOMA**

Glaucoma, characterized by the progressive loss of retinal ganglion cells (RGCs), is an optic neuropathy with no current effective treatment to control the ganglion cell degeneration[1,2]. The management of glaucoma focuses on the proactive prevention of its progression, rendering it a chronic medical condition that necessitates lifelong care. The literature review reveals compelling evidence of a statistically significant association between glaucoma and elevated levels of anxiety and depression[3-10]. Owing to the lack of symptoms, the persisting nature of the debilitation, nature, and the looming possibility of blindness, glaucoma frequently places a psychological weight on individuals[11,12]. Individuals diagnosed with glaucoma are at an elevated risk of developing depression, a correlation substantiated by various studies. Notably, Studies from Taiwan, Japan, and Singapore collectively revealed a significant association between glaucoma and depression. In Taiwan, a retrospective cohort study involving 8777 glaucoma patients and 35108 controls showed a significantly higher hazard of depression (*P* < 0.0001)[4]. In a Japanese case-control study demonstrated elevated rates of anxiety (13.0%, *P* = 0.030) and depression (10.9%, *P* = 0.026) among 230 primary open-angle glaucoma (POAG) patients[3]. Meanwhile, in Singapore, a cross-sectional study with 15,865 glaucoma cases and 77014 controls highlighted that individuals receiving Selective Serotonin Reuptake Inhibitors had a greater risk of glaucoma incidence [odds ratio (OR): 1.39; 95% confidence interval (95%CI): 1.29-1.50][5].

In a study involving 6760 participants aged 40 years and older within the National Health and Nutrition Examination Survey, those diagnosed with glaucoma exhibited a higher prevalence of depression (10.9%, SEM: 2.20%) compared to those without glaucoma (6.9%, SEM: 0.62%). The association remained significant after adjusting for demographic factors but lost significance when considering self-reported general health[7].

Shin *et al*[6], in their retrospective case-control study spanning 2 years and involving 251 eyes diagnosed with open-angle glaucoma, observed a significant incidence of anxiety and depression in affected individuals. Similarly, Zhou *et al*[9] found high rates of anxiety and depression in Chinese glaucoma patients, with the prevalence of anxiety and depression being 22.92% and 16.40%, respectively.

Amidst the body of research on this subject, the presence of some conflicting results from studies conducted across diverse global regions introduced a layer of intricacy to the overall understanding of the subject. European cohort study published by Rezapour *et al*[13], involving 293 participants, revealed no significant association between self-reported glaucoma and depression or anxiety. The prevalence rates for depression (6.6%) and anxiety (5.3%) among individuals with glaucoma were comparable to those without glaucoma (7.7% and 6.6%). Adjusted odds ratios indicated no link between self-reported glaucoma and depression (OR: 1.10, *P* = 0.80) or anxiety (OR: 1.48, *P* = 0.35)[13]. This lack of association persisted even after adjusting for various factors, including socio-demographic variables and health parameters. Consistent with these findings, in both the Australian study by Eramudugolla *et al*[14] and the Beijing Eye Study conducted by Jonas *et al*[15], there was no evidence supporting elevated rates of depressive or anxiety symptoms associated with self-reported glaucoma. Cumurcu *et al*[16] found a correlation between pseudoexfoliative glaucoma (PXG) and depressive symptoms using assessments like the Diagnostic and Statistical Manual of Mental Disorders-IV interview, Hamilton Depression Rating Scale, Hamilton Anxiety Rating Scale, Mini Mental State Examination, and Montgomery-Asberg Depression Rating Scale. However, they noted no significant difference in anxiety levels among PXG, POAG, and control groups. In a study performed on the Israeli population, Weiss *et al*[17] discovered a depression rate in glaucoma patients similar to that of the general Israeli population, and despite depression itself not being directly linked to non-compliance, a positive correlation was observed between the severity of depression and the level of non-compliance in these patients (*P* = 0.04).

The mental health burden in glaucoma patients are influenced by various factors, including the perpetual fear of potential blindness, financial strain, and disruption to daily activities[18,19]. Insightful studies have explored nuanced risk factors for depression in glaucoma patients, such as accelerated progression of visual impairment, advanced disease stages, female gender, substance abuse, and, in some cases, advanced age[4,20]. Younger age was found to be a significant risk factor for anxiety, irrespective of demographic and clinical variables, as indicated by a study that uncovered significant negative relationships between age and the Hospital Anxiety and Depression Scale-Anxiety (HADS-A) subscore both with (*b* = -0.046, *P* = 0.0008) and without (*b* = -0.043, *P* = 0.0022) adjusting for these factors; furthermore, older age and increasing glaucoma severity were identified as risk factors for depression in glaucoma patients[21]. In contrast, an extensive study conducted in North Carolina discovered that advanced age did not elevate the likelihood of depression[18]. Onwubiko *et al*[22] identified high rates of anxiety (44.0%) and depression (41.8%) among glaucoma patients in Enugu, Nigeria, with key contributing factors being reduced VA and also, blindness. Poor treatment adherence in glaucoma patients was associated with heightened anxiety, negatively affecting therapeutic outcomes[23]. According to the studies by Mabuchi *et al*[3] and Chen *et al*[4], the use of eye drops and the number of anti-glaucoma medications were not identified as significant risk factors for depression; furthermore, the use of topical β-blockers for glaucoma, showed no significant correlation with depression. The nature and strength of this association seemed to vary across different populations, types of glaucoma, and even treatment modalities for depression/anxiety.

**THE BIDIRECTIONAL RELATIONSHIP: EXPLORING THE UNDERLYING LINK BETWEEN ANXIETY, DEPRESSION, AND GLAUCOMA**

The intricate relationship between glaucoma and anxiety/depression is marked by an interplay of psychological and physiological factors. The diagnosis of chronic diseases can trigger anxiety and depression due to functional limitations, social isolation, relationship loss, guilt, and future uncertainties, while simultaneously, studies suggest that anxiety and depression can either precipitate or worsen chronic conditions[13,24-26]. The progressive vision loss and intricate medication regimens inherent in glaucoma contribute to a heightened vulnerability to mood disorders. Fear of visual deterioration becomes a continual concern. Numerous studies emphasize on the impact of glaucoma on elevating the risk of anxiety and depression[7,13,18,19]. Additionally, alternative research suggested a reciprocal relationship, revealing that a history of anxiety or depression may increase the likelihood of developing glaucoma in individuals identified as glaucoma suspects[6,10]. In a study by Skalicky *et al*[27], a growing incidence of depression was observed as the severity of glaucoma increased. Similarly, Yochim *et al*[28] established a significant correlation between cognitive impairment, memory deficits, and mild-to-moderate depressive symptoms in a cohort of glaucoma patients. After adjusting for age, they noted that 20% of participants manifested memory impairment, while 22% exhibited compromised executive functioning, and 12.2% of individuals displayed mild-to-moderate depressive symptoms.

The interconnection between glaucoma, anxiety, and depression encompasses intricate neurobiological links that affect not only mental health but also the pathophysiological processes that influence the development and progression of this ocular condition. Studies suggest that the degeneration of retinal tissue in glaucoma is linked to an increased risk of depression and sleep disturbances[18,21,29,30]. This association may stem from disruption in the central light input and the psychological challenges posed by the chronic and progressive nature of the condition, along with the impending threat of vision loss. Glaucoma’s impact on RGCs, their axons, and accompanying glial cells leads to distinct structural alterations in the optic disc and retinal nerve fiber layer (RNFL)[31]. The severity of the condition is directly correlated with a reduction in RNFL thickness[32]. The analysis of the optic nerve head (ONH) and RNFL through optical coherence tomography (OCT) is crucial for early glaucoma detection. By combining OCT with perimetry, which assesses the visual field sensitivity, clinicians can obtain a comprehensive understanding of both structural and functional aspects of the visual system. The integration of structural and functional assessments enhances the sensitivity and specificity of glaucoma diagnosis, allowing for earlier intervention and management. RNFL thickness, in particular, serves as a superior indicator compared to ONH measurements. This reflects the function of RGCs and allows for more effective monitoring of disease progression[33]. Agorastos *et al*[29] in their study, found that visual field defects (VFD) in glaucoma are pivotal predictors for depressive symptoms, trait anxiety, and sleep disturbances, with a higher prevalence of these symptoms in severe VFD cases compared to those with minor or no VFD. The research showed that patients with severe VFD faced a significantly increased risk of achieving clinically significant psychometric scores for depression (OR: 4.0; 95%CI: 1.17-13.60), trait anxiety (OR: 6.1; 95%CI: 1.35-27.10), and sleep disturbance (OR: 4.2; 95%CI: 1.36-13.30). Ayaki *et al*[30] demonstrated that sleep disorders in glaucoma patients are associated with visual field loss and mood status, but not significantly linked to structural damage in RGCs. Additionally, Shin *et al*[6] investigated the relationship between anxiety and RNFL thinning in glaucoma patients, uncovering a significant connection with the high anxiety group exhibiting an accelerated rate of RNFL decline (*P* = 0.026), while no notable differences in visual field progression rates were observed between individuals with low and high anxiety or depression within the study cohort.

Intraocular pressure (IOP) is widely acknowledged as the foremost modifiable factor influencing onset or progression of glaucoma. Psychological stress has been documented to increase IOP, and this effect is mediated through the cortisol hormone, which is associated with the hypothalamic-pituitary-adrenal axis[34,35]. The autonomic nervous system (ANS) functions in regulating blood flow and IOP. The emotional responses of anxiety and depression is believed to originate in the amygdala and trigger the release of neurotransmitters and can adversely impact the ANS, stimulating multiple organs. The ANS plays a crucial role in maintaining biological balance by regulating blood flow and IOP; it is also important in the development or progression of glaucoma[36-39]. Frequent emotional fluctuations and persistent anxiety reactions can disrupt the equilibrium in the ANS, potentially exacerbating the risk of glaucoma or contributing to its progression[40]. Recognizing and addressing these multifaceted aspects, including the potential neurobiological links, is crucial for providing comprehensive support to individuals hustling through the complexities of living with glaucoma.

**INTEGRATED APPROACHES TO GLAUCOMA CARE: IMPLICATIONS ON MANAGEMENT**

The intersection of psychological factors, specifically anxiety and depression, with glaucoma management is integral to understanding and improving patient outcomes. The impact of these psychological elements permeates various facets of the disease trajectory, with treatment adherence serving as a focal point. Anxiety and depression may instigate hesitation, making it difficult to adhere to medication and follow-up appointments, thereby compromising the necessary steps to impede disease progression[41]. This compromised adherence becomes a gateway to exacerbated glaucomatous damage, ultimately leading to an unfavorable prognosis[42]. This progression significantly impacts the patient’s overall quality of life. Detecting glaucoma in its early stages is crucial in clinical care to maintain visual function and quality of life[43,44]. Research findings indicate that simply being aware of one’s glaucoma, even in the absence of visual field damage, may have a detrimental effect on the individual’s quality of life[45].

The loss of peripheral visual function in glaucoma patients has cascading impact on daily activities, ranging from driving limitations, increased incidents of bumping into objects, slower walking, and a higher risk of falls. There is also a major jolt on activities like reading, which becomes evident primarily in cases of severe field damage. Although overall physical activity may not show significant difference, substantial reduction is noted with greater visual field loss[46-49]. A study by Sesar *et al*[50] asserts the negative impact of disease progression and predisposing socio-demographic factors on the quality of life in glaucoma patients. Notably, male individuals aged 50 to 69 exhibited the highest Glaucoma Health-Related Quality of Life (GHRQL), followed by those consistently using anti-glaucoma therapy and then those without glaucoma progression. These distinctions were found to be statistically significant (*P* < 0.05) based on responses to two self-administered questionnaires assessing GHRQL[50]. Ajith *et al*[51] also found elevated rates of depression (35.81%) and anxiety (25.0%) among glaucoma patients in their study, comprising 148 subjects with glaucoma and 150 subjects without glaucoma, emphasizing the need for screening protocols using Patient Health Questionnaire, the Generalized Anxiety Disorder scales. They further advocated that the lack of ophthalmic risk factors associated with depression and anxiety accentuated the significance of psychological assessment and collaborative intervention with a psychiatrist. Social isolation, stemming from difficulties in communication and participation, adds to the emotional burden. Slota *et al*[52] stressed the importance of proactive medication concern addressal in glaucoma patients with lower health literacy, in order to enhance adherence, given by their potential reluctance to communicate issues regarding medication side effects and administration. Incorporating psychological support for severe glaucoma patients with reduced vision can enhance communication and treatment adherence[22]. Musa *et al*[53] pointed out the impact of socioeconomic barriers on glaucoma care, urging attention to factors like companionship, transportation, insurance, education, and telemedicine for improved outcomes. Additionally, addressing the stigma associated with vision loss and mental health issues, the constraint of time during medical appointments, limited access to mental health services, and the need for effective coping strategies further complicate the provision of comprehensive care. Birhan *et al*[54] conducted a cross-sectional study involving 423 glaucoma patients, revealing that 50.1% (95%CI: 45.1%-54.5%) of the surveyed individuals employed maladaptive coping strategies, potentially exacerbating mental health challenges. Conversely, Zhou *et al*[55] found a connection between improved mental health regulation and better self-management behavior in glaucoma patients in China. These studies highlight integrating coping strategy care into glaucoma treatment, to encourage positive approaches towards fostering improved overall patient well-being. To effectively address these challenges, a patient-centered approach is essential, incorporating educational initiatives that cover both the ocular and emotional aspects of glaucoma. However, recognizing the emotional toll of vision loss, the coordination of interdisciplinary collaboration among ophthalmologists, psychologists, and other healthcare professionals is crucial to ensure optimal visual outcomes while safeguarding mental and emotional well-being in the face of this challenging ocular condition.

**CONCLUSION**

The evidence synthesized from peer-reviewed literature reiterates the heightened susceptibility of glaucoma patients to mood disorders, attributed to factors such as progressive vision loss, complex medication regimens, and the relentless fear of visual deterioration. The bidirectional interplay between glaucoma and mood disorders, elucidated in this review, highlights the complex dynamics between ocular and emotional health. The impact of anxiety and depression on critical aspects of glaucoma care, including treatment adherence, disease progression, and overall quality of life, has been thoroughly investigated. Recognizing the psychological burden in glaucoma patients has been emphasized to be crucial for holistic and patient-centered care. Conflicting results from studies conducted across diverse global regions introduce complexity to the understanding of the subject, urging the need for further research. Future studies should aim to standardize methodologies, explore cultural and regional differences, and delve deeper into the underlying mechanisms and risk factors associated with anxiety and depression in glaucoma patients.

In conclusion, this review serves as a foundation for ongoing research endeavours to optimize the management of depression and anxiety in individuals with glaucoma. By addressing the psychological aspects of glaucoma care, healthcare providers can strive to enhance patient-centered approaches and contribute to improved outcomes for those grappling with this debilitating condition.

**REFERENCES**

1 **Weinreb RN**, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. *JAMA* 2014; **311**: 1901-1911 [PMID: 24825645 DOI: 10.1001/jama.2014.3192]

2 **Khatib TZ**, Martin KR. Protecting retinal ganglion cells. *Eye (Lond)* 2017; **31**: 218-224 [PMID: 28085136 DOI: 10.1038/eye.2016.299]

3 **Mabuchi F**, Yoshimura K, Kashiwagi K, Shioe K, Yamagata Z, Kanba S, Iijima H, Tsukahara S. High prevalence of anxiety and depression in patients with primary open-angle glaucoma. *J Glaucoma* 2008; **17**: 552-557 [PMID: 18854732 DOI: 10.1097/IJG.0b013e31816299d4]

4 **Chen YY**, Lai YJ, Wang JP, Shen YC, Wang CY, Chen HH, Hu HY, Chou P. The association between glaucoma and risk of depression: a nationwide population-based cohort study. *BMC Ophthalmol* 2018; **18**: 146 [PMID: 29929494 DOI: 10.1186/s12886-018-0811-5]

5 **Chen VC**, Ng MH, Chiu WC, McIntyre RS, Lee Y, Lin TY, Weng JC, Chen PC, Hsu CY. Effects of selective serotonin reuptake inhibitors on glaucoma: A nationwide population-based study. *PLoS One* 2017; **12**: e0173005 [PMID: 28257449 DOI: 10.1371/journal.pone.0173005]

6 **Shin DY**, Jung KI, Park HYL, Park CK. The effect of anxiety and depression on progression of glaucoma. *Sci Rep* 2021; **11**: 1769 [PMID: 33469104 DOI: 10.1038/s41598-021-81512-0]

7 **Wang SY**, Singh K, Lin SC. Prevalence and predictors of depression among participants with glaucoma in a nationally representative population sample. *Am J Ophthalmol* 2012; **154**: 436-444.e2 [PMID: 22789562 DOI: 10.1016/j.ajo.2012.03.039]

8 **Dayal A**, Sodimalla KVK, Chelerkar V, Deshpande M. Prevalence of Anxiety and Depression in Patients With Primary Glaucoma in Western India. *J Glaucoma* 2022; **31**: 37-40 [PMID: 34474423 DOI: 10.1097/IJG.0000000000001935]

9 **Zhou C**, Qian S, Wu P, Qiu C. Anxiety and depression in Chinese patients with glaucoma: sociodemographic, clinical, and self-reported correlates. *J Psychosom Res* 2013; **75**: 75-82 [PMID: 23751243 DOI: 10.1016/j.jpsychores.2013.03.005]

10 **Berchuck S**, Jammal A, Mukherjee S, Somers T, Medeiros FA. Impact of anxiety and depression on progression to glaucoma among glaucoma suspects. *Br J Ophthalmol* 2021; **105**: 1244-1249 [PMID: 32862132 DOI: 10.1136/bjophthalmol-2020-316617]

11 **Jampel HD**, Frick KD, Janz NK, Wren PA, Musch DC, Rimal R, Lichter PR; CIGTS Study Group. Depression and mood indicators in newly diagnosed glaucoma patients. *Am J Ophthalmol* 2007; **144**: 238-244 [PMID: 17560843 DOI: 10.1016/j.ajo.2007.04.048]

12 **Janz NK**, Wren PA, Guire KE, Musch DC, Gillespie BW, Lichter PR; Collaborative Initial Glaucoma Treatment Study. Fear of blindness in the Collaborative Initial Glaucoma Treatment Study: patterns and correlates over time. *Ophthalmology* 2007; **114**: 2213-2220 [PMID: 17490746 DOI: 10.1016/j.ophtha.2007.02.014]

13 **Rezapour J**, Nickels S, Schuster AK, Michal M, Münzel T, Wild PS, Schmidtmann I, Lackner K, Schulz A, Pfeiffer N, Beutel ME. Prevalence of depression and anxiety among participants with glaucoma in a population-based cohort study: The Gutenberg Health Study. *BMC Ophthalmol* 2018; **18**: 157 [PMID: 29954361 DOI: 10.1186/s12886-018-0831-1]

14 **Eramudugolla R**, Wood J, Anstey KJ. Co-morbidity of depression and anxiety in common age-related eye diseases: a population-based study of 662 adults. *Front Aging Neurosci* 2013; **5**: 56 [PMID: 24106477 DOI: 10.3389/fnagi.2013.00056]

15 **Jonas JB**, Wei WB, Xu L, Rietschel M, Streit F, Wang YX. Self-rated depression and eye diseases: The Beijing Eye Study. *PLoS One* 2018; **13**: e0202132 [PMID: 30096194 DOI: 10.1371/journal.pone.0202132]

16 **Cumurcu T**, Cumurcu BE, Celikel FC, Etikan I. Depression and anxiety in patients with pseudoexfoliative glaucoma. *Gen Hosp Psychiatry* 2006; **28**: 509-515 [PMID: 17088167 DOI: 10.1016/j.genhosppsych.2006.09.004]

17 **Weiss GA**, Goldich Y, Bartov E, Burgansky-Eliash Z. Compliance with eye care in glaucoma patients with comorbid depression. *Isr Med Assoc J* 2011; **13**: 730-734 [PMID: 22332441]

18 **Zhang X**, Olson DJ, Le P, Lin FC, Fleischman D, Davis RM. The Association Between Glaucoma, Anxiety, and Depression in a Large Population. *Am J Ophthalmol* 2017; **183**: 37-41 [PMID: 28760639 DOI: 10.1016/j.ajo.2017.07.021]

19 **Wilson MR**, Coleman AL, Yu F, Fong Sasaki I, Bing EG, Kim MH. Depression in patients with glaucoma as measured by self-report surveys. *Ophthalmology* 2002; **109**: 1018-1022 [PMID: 11986112 DOI: 10.1016/s0161-6420(02)00993-4]

20 **Ribeiro Â**, Ribeiro JP, von Doellinger O. Depression and psychodynamic psychotherapy. *Braz J Psychiatry* 2018; **40**: 105-109 [PMID: 28614491 DOI: 10.1590/1516-4446-2016-2107]

21 **Mabuchi F**, Yoshimura K, Kashiwagi K, Yamagata Z, Kanba S, Iijima H, Tsukahara S. Risk factors for anxiety and depression in patients with glaucoma. *Br J Ophthalmol* 2012; **96**: 821-825 [PMID: 22353697 DOI: 10.1136/bjophthalmol-2011-300910]

22 **Onwubiko SN**, Nwachukwu NZ, Muomah RC, Okoloagu NM, Ngwegu OM, Nwachukwu DC. Factors associated with depression and anxiety among glaucoma patients in a tertiary hospital South-East Nigeria. *Niger J Clin Pract* 2020; **23**: 315-321 [PMID: 32134029 DOI: 10.4103/njcp.njcp\_140\_19]

23 **Lešin Gaćina D**, Jandroković S, Vidas Pauk S, Škegro I, Bošković J, Tomić M, Pupić-Bakrač A, Vlašić D. The medication adherence among glaucoma patients during the coronavirus disease 2019 pandemic in Croatia. *Eur J Ophthalmol* 2023; **33**: 333-340 [PMID: 35791501 DOI: 10.1177/11206721221112150]

24 **Bailey PH**. The dyspnea-anxiety-dyspnea cycle--COPD patients' stories of breathlessness: "It's scary /when you can't breathe". *Qual Health Res* 2004; **14**: 760-778 [PMID: 15200799 DOI: 10.1177/1049732304265973]

25 **DeJean D**, Giacomini M, Vanstone M, Brundisini F. Patient experiences of depression and anxiety with chronic disease: a systematic review and qualitative meta-synthesis. *Ont Health Technol Assess Ser* 2013; **13**: 1-33 [PMID: 24228079]

26 **Bogner HR**, Dahlberg B, de Vries HF, Cahill E, Barg FK. Older patients' views on the relationship between depression and heart disease. *Fam Med* 2008; **40**: 652-657 [PMID: 18830841]

27 **Skalicky S**, Goldberg I. Depression and quality of life in patients with glaucoma: a cross-sectional analysis using the Geriatric Depression Scale-15, assessment of function related to vision, and the Glaucoma Quality of Life-15. *J Glaucoma* 2008; **17**: 546-551 [PMID: 18854731 DOI: 10.1097/IJG.0b013e318163bdd1]

28 **Yochim BP**, Mueller AE, Kane KD, Kahook MY. Prevalence of cognitive impairment, depression, and anxiety symptoms among older adults with glaucoma. *J Glaucoma* 2012; **21**: 250-254 [PMID: 21336151 DOI: 10.1097/IJG.0b013e3182071b7e]

29 **Agorastos A**, Skevas C, Matthaei M, Otte C, Klemm M, Richard G, Huber CG. Depression, anxiety, and disturbed sleep in glaucoma. *J Neuropsychiatry Clin Neurosci* 2013; **25**: 205-213 [PMID: 24026713 DOI: 10.1176/appi.neuropsych.12020030]

30 **Ayaki M**, Shiba D, Negishi K, Tsubota K. Depressed visual field and mood are associated with sleep disorder in glaucoma patients. *Sci Rep* 2016; **6**: 25699 [PMID: 27168309 DOI: 10.1038/srep25699]

31 **Leung CK**, Cheung CY, Weinreb RN, Qiu K, Liu S, Li H, Xu G, Fan N, Pang CP, Tse KK, Lam DS. Evaluation of retinal nerve fiber layer progression in glaucoma: a study on optical coherence tomography guided progression analysis. *Invest Ophthalmol Vis Sci* 2010; **51**: 217-222 [PMID: 19684001 DOI: 10.1167/iovs.09-3468]

32 **Bhat KS**, Reddy MV, Pai V. Correlation of retinal nerve fiber layer thickness with perimetric staging in primary open-angle glaucoma - A cross-sectional study. *Oman J Ophthalmol* 2022; **15**: 36-42 [PMID: 35388245 DOI: 10.4103/ojo.ojo\_345\_20]

33 **Leung CK**, Chan WM, Hui YL, Yung WH, Woo J, Tsang MK, Tse KK. Analysis of retinal nerve fiber layer and optic nerve head in glaucoma with different reference plane offsets, using optical coherence tomography. *Invest Ophthalmol Vis Sci* 2005; **46**: 891-899 [PMID: 15728545 DOI: 10.1167/iovs.04-1107]

34 **Abe RY**, Silva TC, Dantas I, Curado SX, Madeira MS, de Sousa LB, Costa VP. Can Psychologic Stress Elevate Intraocular Pressure in Healthy Individuals? *Ophthalmol Glaucoma* 2020; **3**: 426-433 [PMID: 32768362 DOI: 10.1016/j.ogla.2020.06.011]

35 **Vera J**, Redondo B, Álvarez-Rodríguez M, Molina R, Jiménez R. The intraocular pressure responses to oral academic examination: The influence of perceived levels of public speaking anxiety. *Appl Ergon* 2020; **88**: 103158 [PMID: 32678777 DOI: 10.1016/j.apergo.2020.103158]

36 **Martin EI**, Ressler KJ, Binder E, Nemeroff CB. The neurobiology of anxiety disorders: brain imaging, genetics, and psychoneuroendocrinology. *Psychiatr Clin North Am* 2009; **32**: 549-575 [PMID: 19716990 DOI: 10.1016/j.psc.2009.05.004]

37 **Hoehn-Saric R**, McLeod DR, Funderburk F, Kowalski P. Somatic symptoms and physiologic responses in generalized anxiety disorder and panic disorder: an ambulatory monitor study. *Arch Gen Psychiatry* 2004; **61**: 913-921 [PMID: 15351770 DOI: 10.1001/archpsyc.61.9.913]

38 **Park HL**, Jung SH, Park SH, Park CK. Detecting autonomic dysfunction in patients with glaucoma using dynamic pupillometry. *Medicine (Baltimore)* 2019; **98**: e14658 [PMID: 30882629 DOI: 10.1097/MD.0000000000014658]

39 **Pasquale LR**. Vascular and autonomic dysregulation in primary open-angle glaucoma. *Curr Opin Ophthalmol* 2016; **27**: 94-101 [PMID: 26720776 DOI: 10.1097/ICU.0000000000000245]

40 **Wehrwein EA**, Orer HS, Barman SM. Overview of the Anatomy, Physiology, and Pharmacology of the Autonomic Nervous System. *Compr Physiol* 2016; **6**: 1239-1278 [PMID: 27347892 DOI: 10.1002/cphy.c150037]

41 **Sundbom LT**, Bingefors K. The influence of symptoms of anxiety and depression on medication nonadherence and its causes: a population based survey of prescription drug users in Sweden. *Patient Prefer Adherence* 2013; **7**: 805-811 [PMID: 23983459 DOI: 10.2147/PPA.S50055]

42 **Wolfram C**, Stahlberg E, Pfeiffer N. Patient-Reported Nonadherence with Glaucoma Therapy. *J Ocul Pharmacol Ther* 2019; **35**: 223-228 [PMID: 30897019 DOI: 10.1089/jop.2018.0134]

43 European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition - Chapter 3: Treatment principles and options Supported by the EGS Foundation: Part 1: Foreword; Introduction; Glossary; Chapter 3 Treatment principles and options. *Br J Ophthalmol* 2017; **101**: 130-195 [PMID: 28559477 DOI: 10.1136/bjophthalmol-2016-EGSguideline.003]

44 Glaucoma: Diagnosis and Management of Chronic Open Angle Glaucoma and Ocular Hypertension. London: National Collaborating Centre for Acute Care (UK); 2009 Apr- [PMID: 21938863]

45 **Odberg T**, Jakobsen JE, Hultgren SJ, Halseide R. The impact of glaucoma on the quality of life of patients in Norway. I. Results from a self-administered questionnaire. *Acta Ophthalmol Scand* 2001; **79**: 116-120 [PMID: 11284746 DOI: 10.1034/j.1600-0420.2001.079002116.x]

46 **Nelson P**, Aspinall P, Papasouliotis O, Worton B, O'Brien C. Quality of life in glaucoma and its relationship with visual function. *J Glaucoma* 2003; **12**: 139-150 [PMID: 12671469 DOI: 10.1097/00061198-200304000-00009]

47 **Ramulu PY**, Maul E, Hochberg C, Chan ES, Ferrucci L, Friedman DS. Real-world assessment of physical activity in glaucoma using an accelerometer. *Ophthalmology* 2012; **119**: 1159-1166 [PMID: 22386950 DOI: 10.1016/j.ophtha.2012.01.013]

48 **Aspinall PA**, Johnson ZK, Azuara-Blanco A, Montarzino A, Brice R, Vickers A. Evaluation of quality of life and priorities of patients with glaucoma. *Invest Ophthalmol Vis Sci* 2008; **49**: 1907-1915 [PMID: 18436824 DOI: 10.1167/iovs.07-0559]

49 **Ramulu P**. Glaucoma and disability: which tasks are affected, and at what stage of disease? *Curr Opin Ophthalmol* 2009; **20**: 92-98 [PMID: 19240541 DOI: 10.1097/ICU.0b013e32832401a9]

50 **Sesar I**, Pušić-Sesar A, Jurišić D, Sesar A, Merdžo I, Ćavar I. HEALTH-RELATED QUALITY OF LIFE IN PRIMARY OPEN-ANGLE GLAUCOMA PATIENTS. *Acta Clin Croat* 2020; **59**: 623-631 [PMID: 34285433 DOI: 10.20471/acc.2020.59.04.08]

51 **Ajith BS**, Najeeb N, John A, Anima VN. Cross sectional study of depression, anxiety and quality of life in glaucoma patients at a tertiary centre in North Kerala. *Indian J Ophthalmol* 2022; **70**: 546-551 [PMID: 35086235 DOI: 10.4103/ijo.IJO\_1389\_21]

52 **Slota C**, Sayner R, Vitko M, Carpenter DM, Blalock SJ, Robin AL, Muir KW, Hartnett ME, Sleath B. Glaucoma patient expression of medication problems and nonadherence. *Optom Vis Sci* 2015; **92**: 537-543 [PMID: 25875690 DOI: 10.1097/OPX.0000000000000574]

53 **Musa I**, Bansal S, Kaleem MA. Barriers to Care in the Treatment of Glaucoma: Socioeconomic Elements That Impact the Diagnosis, Treatment, and Outcomes in Glaucoma Patients. *Curr Ophthalmol Rep* 2022; **10**: 85-90 [PMID: 35911786 DOI: 10.1007/s40135-022-00292-6]

54 **Birhan GS**, Belete GT, Eticha BL, Ayele FA. Magnitude of Maladaptive Coping Strategy and Its Associated Factors Among Adult Glaucoma Patients Attending Tertiary Eye Care Center in Ethiopia. *Clin Ophthalmol* 2023; **17**: 711-723 [PMID: 36895951 DOI: 10.2147/OPTH.S398990]

55 **Zhou W**, Lin H, Ren Y, Lin H, Liang Y, Chen Y, Zhang S. Mental health and self-management in glaucoma patients during the COVID-19 pandemic: a cross-sectional study in China. *BMC Ophthalmol* 2022; **22**: 474 [PMID: 36474185 DOI: 10.1186/s12886-022-02695-2]

**Footnotes**

**Conflict-of-interest statement:** There are no conflicts of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** December 4, 2023

**First decision:** January 15, 2024

**Article in press:**

**Specialty type:** Ophthalmology

**Country/Territory of origin:** India

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Gunlu A, Turkey; Hosak L, Czech Republic **S-Editor:** Chen YL **L-Editor:** A **P-Editor:**

**Table 1 Summary of 8 selected studies on glaucoma and anxiety/depression association**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Ref.** | **Region** | **Study design** | **No. of patient** | **Results** | **Key findings** |
| Mabuchi *et al*[3], 2008 | Japan | Case control study | 230 POAG patients; 230 controls | Prevalence of anxiety: 13.0% (*P* = 0.030); depression: 10.9% (*P* = 0.026) | POAG was related to anxiety and depression |
| Wang *et al*[7], 2012 | United States | Cross sectional study | 453 glaucoma patients | 10.9% prevalence of depression among self-reported glaucoma patients | Visual function parameters were associated with depression |
| Zhou *et al*[9], 2013 | China | Cross sectional study | 506 glaucoma patients | Prevalence of anxiety: 22.92%; depression: 16.40% | High anxiety and depression rates exist among Chinese glaucoma patients |
| Chen *et al*[5], 2017 | Taiwan | Case control study | 15865 glaucoma patients; 77014 controls | SSRI use linked to increased glaucoma risk (OR: 1.39, 95%CI: 1.29-1.50) | SSRIs use associated with glaucoma |
| Chen *et al*[4], 2018 | Taiwan | Cohort study | 8777 glaucoma patients; 35108 controls | In 11 yr follow up period, incidence of depression: Glaucoma group = 5.9% depression, control group = 3.2% | Patients with glaucoma are at significantly greater risk of developing depression |
| Berchuck *et al*[10], 2021 | United States | Cohort study |  3259 glaucoma suspects; 28% (911 cases) diagnosed with glaucoma during follow-up | Prevalence of anxiety: 32%; depression: 33% | Prior anxiety or anxiety with depression history raises the risk of developing glaucoma in glaucoma suspects |
| Shin *et al*[6], 2021 | Korea | Case control study | 251 eyes with POAG | Anxiety linked to disc hemorrhage, peak IOP, and RNFL thinning rate (*P* = 0.017, *P* = 0.046, *P* = 0.026); depression tied to visual field mean deviation and heart rate variability (*P* = 0.003, *P* = 0.006) | Anxiety increase the risk of glaucoma progression and they are also associated with IOP profile and disc hemorrhage |
| Dayal *et al*[8], 2022 | India | Cross sectional study | 200 patients | Mean HADS-anxiety = 4.5 (SD = 3.4); HADS-depression = 4.1 (SD = 3.8) | Visual loss in glaucoma correlates with anxiety and depression symptoms, regardless of disease duration |

POAG: Primary open-angle glaucoma; HADS: Hospital Anxiety and Depression Scale-Anxiety; SSRI: Selective serotonin reuptake inhibitors; IOP: Intraocular pressure; 95%CI: 95% confidence interval; OR: Odds ratio.